Reuters logo
BRIEF-Pharma Mar unit starts Phase III study with drug to treat dry eye syndrome
May 30, 2017 / 5:01 AM / 4 months ago

BRIEF-Pharma Mar unit starts Phase III study with drug to treat dry eye syndrome

May 30 (Reuters) - PHARMA MAR SA:

* SAID ON MONDAY THAT ITS UNIT SYLENTIS SAU HAD INITIATED THE FIRST PHASE III STUDY WITH ITS INVESTIGATIONAL DRUG SYL1001 FOR THE TREATMENT OF DRY EYE SYNDROME

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below